- In May 2024, Johnson & Johnson Services Inc. announced the phase 3 results of its Crohn's disease program for Tremfya. The trial data showed that Tremfya outperformed Stelara in all endoscopic patients within the study group, highlighting its superior efficacy. This marks a significant advancement in Crohn's disease treatment
- In April 2024, Takeda Pharmaceutical Company Limited received FDA approval for subcutaneous administration of Entyvio following initial IV induction therapy. Entyvio is used to treat patients with severely active Crohn’s disease, offering a more convenient treatment option post-induction
- In October 2023, Johnson & Johnson Services, Inc. released phase 3 clinical trial data for Tremfya (guselkumab), evaluating its safety and efficacy for active ulcerative colitis. The study showed a 77% overall clinical response rate, with early symptom improvement observed in patients. This highlights Tremfya's potential as a treatment for ulcerative colitis
- In June 2023, Lilly's Omvoh (mirikizumab) gained market authorization from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for treating ulcerative colitis. This approval marks an important step in expanding treatment options for patients with the condition
- In February 2023, AbbVie announced that the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) approved RINVOQ, a JAK inhibitor, for treating moderate to severe Crohn's disease. This approval is for patients who did not respond adequately to conventional therapies
Frequently Asked Questions
The market is segmented based on Segmentation, By Type (Microscopic Colitis, Ulcerative Colitis, and Crohn's Disease), Treatment (Medication, Surgery, and Others), Dosage Form (Tablet, Capsule, Injections, and Others), Route of Administration (Oral, Parenteral, and Others), Diagnosis (Imaging Procedures, Endoscopic Procedures, and Lab Tests), End-Users (Hospitals, Specialty Clinics, Homecare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others) – Industry Trends and Forecast to 2031
.
The Global Inflammatory Bowel Diseases Market size was valued at USD 22.42 USD Billion in 2023.
The Global Inflammatory Bowel Diseases Market is projected to grow at a CAGR of 5.3% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
